Productos Medix, S.A.

What Productos Medix, S.A. does

Productos Medix, S.A. de C.V. is a Mexican pharmaceutical company founded in 1940 and headquartered in Mexico City (Calzada del Hueso No. 39, Colonia Ex Ejido de Santa Ursula Coapa, Coyoacán). The company specializes in metabolic and endocrine health pharmaceuticals, with a core therapeutic focus on overweight and obesity and their associated comorbidities including type 2 diabetes, hypothyroidism, non-alcoholic fatty liver disease, dyslipidemia, hypertension, and insomnia.

Medix's product portfolio includes COFEPRIS-approved antiobesity medications (both centrally- and peripherally-acting), Cronocaps (extended-release melatonin in 3mg and 5mg doses for insomnia), metformin for diabetes/prediabetes, levothyroxine (T4) and liothyronine (T3) for hypothyroidism, and a hepatology line comprising pioglitazone, vitamin E, liraglutide, and a silibinin-phosphatidylcholine-alpha lipoic acid complex for non-alcoholic fatty liver disease. The company also operates Health Mart, S.A. de C.V. as a wholly-owned adjacent subsidiary.

The business model is built on prescription and OTC pharmaceutical product sales distributed through Mexican pharmacies. Medix executes a dual-channel GTM approach: a consumer-facing digital platform (medix.com.mx) offering health education content on overweight, obesity, and metabolic conditions, and a separate professional portal (medicalmedix.com) serving healthcare professionals with clinical and prescribing information. A call center (800 366 3349) handles consumer inquiries. The company employs 51–100 staff, maintains active social media presence (Facebook, LinkedIn, YouTube), and is privately held — having received a $32M investment from WAMEX Private Equity in 2013.

Name

Productos Medix, S.A.

Legal name

Productos Medix, S.A. de C.V.

Website

https://medix.com.mx

Company type

Private

Founded year

1940

Operating status

Operating

Headcount range

51–100 employees

Short description

Productos Medix is a privately held Mexican pharmaceutical company founded in 1940 that develops and markets COFEPRIS-approved medications for obesity, thyroid disorders, insomnia, diabetes, and fatty liver disease, distributed through Mexican pharmacies via dual consumer and healthcare professional channels.

Ownership category

akta.pro rank

Product category

Pharmaceuticals - Metabolic and Endocrine Health

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Obesity pharmaceuticals
• Metabolic health drugs
• Thyroid hormone therapy
• Antiobesity medications
• Pharmaceutical manufacturing Mexico

Headquarters

HQ city

Ciudad De Dolores Hidalgo

HQ country

Mexico

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Medix generates revenue through the sale of prescription and over-the-counter pharmaceutical products targeting metabolic and endocrine health conditions, primarily distributed through pharmacies in Mexico.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Productos Medix develops, manufactures, and supplies prescription and over-the-counter pharmaceutical products focused on obesity, metabolism, and central nervous system disorders. The portfolio includes antiobesity medications (centrally and peripherally acting, COFEPRIS-approved), thyroid hormone replacement therapies (levothyroxine and T4+T3 combination), melatonin-based sleep aids, and hepatology drugs for non-alcoholic fatty liver disease. Products are distributed primarily through Mexican pharmacies, complemented by consumer and healthcare-professional educational digital platforms.

Product overview

Productos Medix, S.A. operates as a pharmaceutical/healthcare company offering a portfolio of prescription medications focused on metabolic and endocrine conditions, particularly overweight/obesity management and related comorbidities. The product portfolio includes: Cronocaps (prolonged-release melatonin for insomnia); Metformin for diabetes and prediabetes management; Levotiroxina (levothyroxine) and Liotironina (T3) for hypothyroidism treatment; and several hepatology medications including Pioglitazona, Vitamina E, Liraglutida, and a Silibinin-Phosphatidylcholine-Alpha Lipoic Acid complex for non-alcoholic fatty liver disease. The company also publishes extensive health education content addressing conditions such as obesity, diabetes, hypertension, dyslipidemia, fatty liver disease, hypothyroidism, and sleep disorders. The primary consumer-facing website (medix.com.mx) serves as an informational and educational platform, with a separate portal (medicalmedix.com) dedicated to healthcare professionals.

Differentiator

Problem solved

Functional benefit

Brands

• Cronocaps: Melatonin extended-release capsules in 3mg and 5mg doses, for insomnia treatment.

Products and services

• Cronocaps Cronocaps is a prolonged-release melatonin medication containing 30 capsules available in 3 mg and 5 mg doses, formulated to mimic the natural secretion pattern of melatonin in the body. It is used for the treatment of insomnia, particularly in patients over 55 years of age.
• Metformin (Metformina) Metformin is an oral antidiabetic medication used for the treatment of prediabetes and type 2 diabetes mellitus. Studies demonstrate that the addition of metformin to lifestyle changes can reduce progression to diabetes by 58%.
• Levotiroxina (Levothyroxine / T4) Levothyroxine is a synthetic T4 hormone used as the preferred form of thyroid hormone replacement for the treatment of hypothyroidism, typically administered in small doses and gradually increased.
• Liotironina (Liothyronine / T3) Liothyronine (T3) is used in combined therapy with levothyroxine for hypothyroidism treatment, with clinical trials demonstrating improvement in symptoms, concentration, mood, and blood cholesterol when added to levothyroxine therapy.
• Pioglitazona (Pioglitazone) Pioglitazone is a medication studied for non-alcoholic fatty liver disease treatment, known to reduce hepatic inflammatory activity and possibly fibrosis, though weight gain is its most frequent adverse event.
• Vitamina E (Vitamin E) Vitamin E is recommended for patients with non-alcoholic fatty liver disease without diabetes or cirrhosis, used for its antioxidant properties as part of pharmacological intervention.
• Liraglutida (Liraglutide) Liraglutide reduces hepatic fat content, improves liver function and glycosylated hemoglobin, and is effective in resolving steatohepatitis and reducing body weight in patients with fatty liver disease.
• Complex Silibina, Fosfatidilcolina y Ácido Alfa Lipoico (Silibinin, Phosphatidylcholine and Alpha Lipoic Acid Complex) An antioxidant complex combining silibinin, phosphatidylcholine, and alpha lipoic acid used in non-alcoholic fatty liver disease treatment, demonstrating improvement in histology, fibrosis markers, and metabolic profile, particularly in patients with type 2 diabetes.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Novo Nordisk: Global leader in diabetes and obesity therapy (insulin, GLP-1, Wegovy, Ozempic); serves the same Mexican cardiometabolic patient pool and competes with Medix's liraglutide and antiobesity products.
• Eli Lilly: Global pharmaceutical incumbent with major diabetes (Humalog, Mounjaro, Zepbound) and endocrinology franchises; expanding aggressively in Mexican obesity/metabolic markets where Medix also operates.

Direct peers

• Laboratorios Silanes: Mexican specialty pharmaceutical company focused on metabolic, cardiometabolic, and chronic disease therapies; comparable scale and therapeutic overlap with Medix's obesity/diabetes/thyroid portfolio.
• Landsteiner Scientific: Mexican pharmaceutical manufacturer focused on branded specialty and chronic-disease therapies including metabolic and endocrine categories; similar mid-sized domestic footprint.
• Laboratorios Pisa: One of Mexico's largest domestic pharma manufacturers with a broad branded-generic and specialty portfolio including metabolic and endocrine therapies; comparable pharmacy-channel distribution model.
• Laboratorios Sanfer: Mexican specialty pharma with branded prescription products across metabolic, cardiovascular, and endocrine therapeutic areas; competes directly for the same physician and pharmacy relationships.
• Laboratorios Liomont: Mexican pharmaceutical company producing branded and specialty products across metabolic, CNS, and chronic-disease categories; similar DTC-plus-professional channel strategy and therapeutic focus.

Regional players

• Eurofarma Laboratórios: Brazil's largest domestic pharmaceutical company with branded specialty and metabolic portfolios; comparable Latin American mid-market specialty pharma model with regional (not Mexican) overlap.
• Aché Laboratórios: Brazilian pharmaceutical company with branded prescription products across metabolic, cardiovascular, and CNS categories; similar mid-sized emerging-market specialty pharma profile outside Mexico.
• Cristália: Brazilian pharmaceutical manufacturer with branded specialty and hospital products including endocrine and metabolic therapies; comparable Latin American regional specialty pharma footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@medix8315
• Facebookfacebook.com/medixMx
• LinkedInlinkedin.com/company/medixmexico

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Productos Medix, S.A.